Skip to main content
. Author manuscript; available in PMC: 2009 Aug 17.
Published in final edited form as: Cancer Biol Ther. 2008 May 7;7(5):709–717. doi: 10.4161/cbt.7.5.5713

Figure 3.

Figure 3

CDDO C-28 derivatives deplete the S-phase in SK-N-AS neuroblastoma cells. (A) Cell cycle profile (percentage of cells in each cell cycle phase) of SK-N-AS cells treated and control by FACS analysis. SK-N-AS cells were exposed to 200 nM of CDDO-Me, CDDO-IM, CDDO-TFEA or DMSO control for 24 hours. Cells were then pulsed with BrdU for 3 h. BrdU and total DNA content were evaluated by FACS analysis. Experiments were performed in triplicate. Error bars represent standard errors of means for each set of data. *p < 0.05, **p < 0.01, when compared to control. (B) CDDO-Me induces apoptotic morphological changes in neuroblastoma cells. Neuroblastoma cell lines 15N and SK-N-AS) were treated with 250 nM CDDO-Me for 10 hours. After treatment, cells were analyzed by cytospin. Black arrows, membrane blebbing; black arrowheads, nuclear fragmentation.